What is Sarepta Therapeutics' stock symbol?
Sarepta Therapeutics trades on the NASDAQ under the ticker symbol "SRPT."
Where is Sarepta Therapeutics' stock going? Where will Sarepta Therapeutics' stock price be in 2017?
19 equities research analysts have issued twelve-month price objectives for Sarepta Therapeutics' shares. Their predictions range from $5.00 to $106.00. On average, they anticipate Sarepta Therapeutics' share price to reach $62.00 in the next year.
When will Sarepta Therapeutics announce their earnings?
Sarepta Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.
What are analysts saying about Sarepta Therapeutics stock?
Here are some recent quotes from research analysts about Sarepta Therapeutics stock:
- Needham & Company LLC analysts commented, "We expected the PRV would fetch a higher price, closer to $300M or more based on the sale price of the last two rare pediatric PRVs ($245M in May 2015 and $350M in August 2015). Sarepta sold the voucher through an auction-like process, implying that the market value for PRVs has softened. While the lower sales price leads to our modest price target reduction (to $78 from $81), we believe the more important outcome is that Sarepta should now have sufficient cash to reach positive cash flow from Exondys sales even if it sees more sluggish growth than we anticipate in 2017." (2/22/2017)
- Robert W. Baird analysts commented, " (2/21/2017)
Oppenheimer Holdings, Inc. analysts commented, "We reiterate our BUY rating on shares of ISRG following Medtronic’s investor and analyst meeting on Monday. Medtronic provided details regarding its surgical robotic system for the first time. Given palpable investor concern about the prospects of MDT entering the robotic surgery fray, details given by MDT about its robotic surgery platform portended neutral to ISRG at worst, in our view. To wit, based on the details given during the meeting, including timing (seemingly at least 18-24 months away), ISRG should enjoy a clear field in the surgical robotics market over the near/ medium term. Importantly, MDT intimated its intended mode of growth in the robotic surgery space would initially be market development rather than competitive share. Indeed, noting >60% of surgeries are still performed in an open setting, MDT plans to target a vast array of general surgical procedures under-penetrated by robotic surgery yet well positioned for MIS techniques. While MDT will eventually target procedural markets in which ISRG does business (colorectal, thoracic), we believe growth opportunities for ISRG in the near/medium term are plentiful, primarily via domestic growth in general surgery procedures and international expansion of dvP and dvH, not to mention incremental opportunities portended by new products (i.e. SP). In sum, we maintain our bullish outlook on the stock, and reiterate our $700 year-end price target. Key notes on MDT’s upcoming platform: Engineering: The company’s robotics platform has been under development for ~3 years, with a large portion of the technology acquired via the Covidien merger." (6/3/2016)
Who owns Sarepta Therapeutics stock?
Sarepta Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (4.83%), FMR LLC (2.19%), Two Sigma Investments LP (0.48%), Fred Alger Management Inc. (0.23%), Guggenheim Capital LLC (0.16%) and Highland Capital Management LP (0.16%). Company insiders that own Sarepta Therapeutics stock include David T Howton, Edward M Md Kaye, Jayant Aphale, M Kathleen Behrens and Sandesh Mahatme.
Who sold Sarepta Therapeutics stock? Who is selling Sarepta Therapeutics stock?
Sarepta Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Guggenheim Capital LLC, State Board of Administration of Florida Retirement System, National Planning Corp and United Capital Financial Advisers LLC. Company insiders that have sold Sarepta Therapeutics stock in the last year include David T Howton, Edward M Md Kaye, Jayant Aphale and Sandesh Mahatme.
Who bought Sarepta Therapeutics stock? Who is buying Sarepta Therapeutics stock?
Sarepta Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Highland Capital Management LP, Allianz Asset Management AG, Renaissance Technologies LLC, I.G. Investment Management LTD., AQR Capital Management LLC, Russell Investments Group Ltd. and Numeric Investors LLC.
How do I buy Sarepta Therapeutics stock?
Shares of Sarepta Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Sarepta Therapeutics stock cost?
One share of Sarepta Therapeutics stock can currently be purchased for approximately $32.02.